CALIFON, NJ, Sept. 15, 2011 /CNW/ - PediatRx Inc. ("PediatRx") (OTCBB:
PEDX), a hospital specialty company with a current focus on oncology
supportive care, today announced the appointment of Paul J. Richardson
to its Board of Directors. As a pharmaceutical senior executive with
more than 30 years of experience in US and global commercialization,
product and business development, and organizational leadership, Mr.
Richardson brings significant expertise in sales management, business
development, licensing, acquisition, commercialization and strategic
marketing to PediatRx.
"We are privileged to welcome a pharmaceutical executive of Paul's
caliber to our Board. His track record of success coupled with his
experience and insight should contribute significantly to the oversight
and operations of PediatRx," said Dr. Cameron Durrant, founder of
"PediatRx is doing important work in the field of oncology supportive
care and has a number of opportunities upon which to capitalize going
forward," said Mr. Richardson. "I am excited to be working with both
the Board and the executive team as we move the company to the next
Mr. Richardson most recently held the position of Regional President of
Pfizer's North America Specialty Care business unit with direct
accountability for the delivery, in 2010, of over $4.5 billion of
annual revenue and associated profitability targets. He has also held
other senior roles within Pfizer and Pfizer heritage companies during
his career. Mr. Richardson holds a BSc (honors) in Physiology from the
University of Leeds, United Kingdom.
PediatRx Inc. (www.pediatrx.com) is a hospital specialty pharmaceutical company which focuses on
treatments for patients suffering from serious conditions requiring
hospitalization with an initial focus on oncology supportive care.
PediatRx trades on the OTCBB under the ticker symbol PEDX.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking
statements are projections of events, revenues, income, future
economics, research, development, reformulation, product performance or
management's plans and objectives for future operations. In some cases
you can identify forward-looking statements by the use of terminology
such as "may", "should", "anticipates", "believes", "expects",
"intends", "forecasts", "plans", "future", "strategy", or words of
similar meaning. Forward-looking statements in this press release
include the company's expectation that Mr. Richardson's track record of
success and experience should contribute significantly to the oversight
and operations of the company and Mr. Richardson's belief that the
company has a number of opportunities upon which to capitalize going
forward. While these forward-looking statements and any assumptions
upon which they are based are made in good faith and reflect current
judgment regarding the direction of the business operations of
PediatRx, actual results will almost always vary, sometimes materially,
from any estimates, predictions, projections, assumptions or other
future performance suggested in this press release. These statements
are predictions and involve known and unknown risks, uncertainties and
other factors, including the risk that PediatRx cannot execute its
business plan for lack of capital or other resources, distribution,
partnering or licensing/acquisition opportunities, as well as the risks
described in the periodic disclosure documents filed on EDGAR by
PediatRx, copies of which are also available on the company's website.
Any of these risks could cause PediatRx or its industry's actual
results, levels of activity, performance or achievements to be
materially different from those expressed or implied by the
forward-looking statements in this press release. Except as required
by applicable law, including the securities laws of the United States,
PediatRx does not intend to update any of the forward-looking
statements to conform these statements to actual results.
SOURCE PediatRx Inc.
For further information:
Research & Business Development
+1 908 975 0753